GCG and asthma: There is an urgent need for large randomized, controlled, clinically comparative trials of different GLP-1 RAs in the setting of co-occurring asthma, diabetes, and/or obesity. In sum, we recommend that all clinicians (MDs, NPs, and PA) strongly consider the use of GLP-1 RAs in the early stage of asthma in obese diabetics to prevent or slow down the beginning of pathological remodeling and permanent lung damage.